
Rewriting the Treatment Playbook for MDS/MPN and Myelofibrosis
In this Editor’s Special episode of The HemOnc Pulse, MD Anderson Cancer Center’s Naval Daver, MD, and Naveen Pemmaraju, MD, discuss MDS/MPN overlap conditions and research examining combination therapy with ruxolitinib and azacitidine (AZA), including its potential to improve disease response, symptom control, and outcomes.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.